EICHORPublic-registry site landscape for NCT06863467, “Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.”, a Renal Insufficiency, Chronic study sponsored by Revelation Biosciences, Inc. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT06863467 (registry record) |
| Study title | Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease. |
| Official title | A Phase 1b, Randomized, Placebo-Controlled, Single-Blind, Single Ascending Dose Study in Subjects With Stage 3 or 4 Chronic Kidney Disease |
| Sponsor | Revelation Biosciences, Inc |
| Condition(s) | Renal Insufficiency, Chronic; Chronic Kidney Disease stage3; Chronic Kidney Disease stage4 |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 3 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT06863467.
Eichor generates a preliminary site-risk snapshot for NCT06863467 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
